Glucagon like Peptide

The rise of glucagon-like peptide-1 (GLP‑1) receptor agonists (GLP‑1 RAs) such as semaglutide and tirzepatide has transformed modern metabolic medicine. Once used primarily for type 2 diabetes, these drugs are now prescribed widely for obesity, cardiometabolic risk reduction, and metabolic dysfunction more broadly.1 Their effectiveness has been described as unprecedented,2 with some ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...
Key Details About Translated Article Glucagon Like Peptide 1 Agonists For Treating

INTRODUCTION The development of glucagon-like-peptide-1 (GLP-1) receptor agonists (GLP-1RAs), which has revolutionised the management of both type 2 diabetes and obesity, represents a story of long-term discovery, driven as much by serendipity as targeted research, with effective, but arguably overdue, translation-the breadth of which has been unanticipated.
This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor (GLP-1R) agonists , tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding ...

Useful Notes on Translated Article Glucagon Like Peptide 1 Agonists For Treating
Abstract Glucagon-like peptide-1 receptor agonists , or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity. More recently, it has become clear that these receptors are widely distributed throughout the central nervous system (CNS), which has raised the possibility of repurposing these drugs for neurological disorders.
Glucagon-like peptide-1 (GLP-1) agonists are a class of medicines used to treat type 2 diabetes by lowering blood sugar levels. Some are used for weight loss in people with obesity.

Overview of Translated Article Glucagon Like Peptide 1 Agonists For Treating
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic options for addressing Type-2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., all notable GLP-1RA, have gained attention owing to their favourable pharmacological properties and clinical efficacy. Aims
Summary Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that pro-mote glucose-mediated insulin release and are used to treat type 2 diabetes mel-litus and obesity.

Prescribing Trends of Glucagon
This cross-sectional study examines the US prescribing trends of glucagon-like peptide 1 (GLP-1) receptor agonists among individuals with type 2 diabetes and/or obesity.







The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types ...